Companies: 10,795·Total market cap: $144.5T

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc.

ANTXNASDAQHealthcare● Active

$4.76

+$0.02(+0.42%)

Market Cap$130433634

P/E Ratio—

52W High$6.91

52W Low$1

Avg Volume298K

Open$4.76

Beta-0.98

Net Income Financials Revenue

AN2 Therapeutics, Inc. (ANTX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

ANTX · net income · updated Jun 15, 2026

Core profitability metrics

ANTX · net income · margin · TTM · CAGR

Net income was −$35.2M for FY2025 (fiscal year ending 2025-12-31), up 31.5% year-over-year. Net profit margin was —.

FY2025 Net Income−$35.2M▲ +31.5% YoY

Trailing 12M (TTM)−$34.6Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change+31.5%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 15, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · ANTX net income history · ANTX profit margin

Annual net income data

ANTX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$35.2M▲ +31.5%—$0

FY2024Loss−$51.3M▲ +20.7%—$0

FY2023Loss−$64.7M▼ 58.1%—$0

FY2022Loss−$41.0M▼ 90.1%—$0

FY2021Loss−$21.5M▼ 58.4%—$0

Net income vs peers (Healthcare)

ANTX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

AN2 Therapeutics, Inc.YOU

ANTX

−$35.2M+31.5%—

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

AN2 Therapeutics, Inc. (ANTX) reported net income of −$35.2M for FY2025 (fiscal year ending 2025-12-31), up 31.5% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

AN2 Therapeutics, Inc. has not yet achieved annual profitability based on available data (7 fiscal years). The company has reported net losses across all available periods.

AN2 Therapeutics, Inc.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "AN2 Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from ANTX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

ANTX net income · 4 questions

AN2 Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $35.2M for FY2025.

is ANTX profitabledoes ANTX make a profitANTX profitabilityANTX profitable company

▸ Source: FMP /income-statement · GAAP · AN2 Therapeutics, Inc. · AN2 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026